Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Cambrex Follows In Dosage Form Trend

by Rick Mullin
November 8, 2010 | A version of this story appeared in Volume 88, Issue 45

Pharmaceutical chemical maker Cambrex has acquired a 51% stake in Zenara Pharma, an India-based specialist in final-dosage-form drug manufacturing and nicotine replacement gums, for about $20 million. Cambrex will buy the remaining 49% of Zenara in 2016. Cambrex competitor AMRI made a similar move into dosage-form drug production last year with the acquisition of Hyaluron. Lonza, meanwhile, failed last year in a bid to acquire Patheon, a major finished-form drug development company./p>

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.